D

Devyser Diagnostics AB
STO:DVYSR

Watchlist Manager
Devyser Diagnostics AB
STO:DVYSR
Watchlist
Price: 129 SEK -1.9% Market Closed
Market Cap: 2.1B SEK
Have any thoughts about
Devyser Diagnostics AB?
Write Note

Relative Value

The Relative Value of one DVYSR stock under the Base Case scenario is 185.24 SEK. Compared to the current market price of 129 SEK, Devyser Diagnostics AB is Undervalued by 30%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

DVYSR Relative Value
Base Case
185.24 SEK
Undervaluation 30%
Relative Value
Price
D
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
10
vs Industry
47
Median 3Y
9.2
Median 5Y
9.2
Industry
7.7
Forward
9.4
vs History
vs Industry
Median 3Y
-29.7
Median 5Y
-29.7
Industry
22.7
Forward
-33.4
vs History
vs Industry
Median 3Y
-29.3
Median 5Y
-29.3
Industry
21.6
vs History
vs Industry
Median 3Y
-15.4
Median 5Y
-15.4
Industry
25.2
vs History
2
vs Industry
19
Median 3Y
3
Median 5Y
3
Industry
2.5
vs History
2
vs Industry
41
Median 3Y
6.9
Median 5Y
6.9
Industry
7.7
Forward
8.8
vs History
2
vs Industry
37
Median 3Y
8.4
Median 5Y
8.4
Industry
9
vs History
vs Industry
Median 3Y
-27.4
Median 5Y
-27.4
Industry
4.2
Forward
-48.1
vs History
vs Industry
Median 3Y
-20.8
Median 5Y
-20.8
Industry
4.1
Forward
-31
vs History
vs Industry
Median 3Y
-20.5
Median 5Y
-20.5
Industry
5.7
vs History
vs Industry
Median 3Y
-12.6
Median 5Y
-12.6
Industry
3.6
vs History
24
vs Industry
28
Median 3Y
6.3
Median 5Y
6.3
Industry
4.6

Multiples Across Competitors

DVYSR Competitors Multiples
Devyser Diagnostics AB Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
SE
Devyser Diagnostics AB
STO:DVYSR
2.2B SEK 10.9 -30.4 -38.7 -26.4
FR
Pharnext SCA
OTC:PNEXF
6T USD 37 888 840.5 -180 080 -218 674.5 -216 179.2
US
Abbvie Inc
NYSE:ABBV
314.7B USD 5.7 61.9 15.4 23.7
US
Amgen Inc
NASDAQ:AMGN
157B USD 4.8 37.1 17.4 32.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.9B USD 10.9 -241.6 24 25.2
US
Gilead Sciences Inc
NASDAQ:GILD
112.2B USD 4 890.3 9.9 9.9
US
Epizyme Inc
F:EPE
94.1B EUR 1 859.4 -474.5 -516.7 -502.9
AU
CSL Ltd
ASX:CSL
133.6B AUD 5.9 32.9 20.3 25.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.6B USD 6 17.8 16.2 18
US
Seagen Inc
F:SGT
39.3B EUR 17.9 -54.9 -59 -53.2
NL
argenx SE
XBRU:ARGX
34.5B EUR 18.6 -130.6 -105.1 -76.6
P/E Multiple
Earnings Growth
SE
D
Devyser Diagnostics AB
STO:DVYSR
Average P/E: 208
Negative Multiple: -30.4
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -180 080 N/A
US
Abbvie Inc
NYSE:ABBV
61.9
412%
US
Amgen Inc
NASDAQ:AMGN
37.1
73%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -241.6
42%
US
Gilead Sciences Inc
NASDAQ:GILD
890.3
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -474.5 N/A
AU
CSL Ltd
ASX:CSL
32.9
65%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.8
43%
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.9 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -130.6 N/A
EV/EBITDA Multiple
EBITDA Growth
SE
D
Devyser Diagnostics AB
STO:DVYSR
Average EV/EBITDA: 17.2
Negative Multiple: -38.7
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -218 674.5 N/A
US
Abbvie Inc
NYSE:ABBV
15.4
28%
US
Amgen Inc
NASDAQ:AMGN
17.4
63%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24
38%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
12%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -516.7 N/A
AU
CSL Ltd
ASX:CSL
20.3
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.2
46%
US
S
Seagen Inc
F:SGT
Negative Multiple: -59 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -105.1 N/A
EV/EBIT Multiple
EBIT Growth
SE
D
Devyser Diagnostics AB
STO:DVYSR
Average EV/EBIT: 22.5
Negative Multiple: -26.4
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -216 179.2 N/A
US
Abbvie Inc
NYSE:ABBV
23.7
88%
US
Amgen Inc
NASDAQ:AMGN
32.9
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.2
44%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -502.9 N/A
AU
CSL Ltd
ASX:CSL
25.3
55%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18
54%
US
S
Seagen Inc
F:SGT
Negative Multiple: -53.2 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -76.6 N/A

See Also

Discover More
Back to Top